Linfoma no-Hodgkin. Avances en el trasplante autólogo de células madre: Revisión crítica

Translated title of the contribution: Non-Hodgkin's lymphoma. Advances in autologous stem cell transplantation: A critical review

Carlos Montero Osorio, J. O. Armitage

Research output: Contribution to journalReview article


The non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality and the trend of this disease is to increase. In the United States of America of 53 900 new cases and 24 400 deaths are estimated in 2002 (1) While patients with aggressive lymphomas can frequently be cured, those with indolent lymphomas, despite a long average survival, have been more difficult to cure. Results indicate that, at least, 40 % to 60 % of patients with NHL eitherfail to achieve a complete remission (CR) or relapse after receiving standard front line therapy. Therefore, the necessity of better treatments is real, particularly in those patients with advanced disease. Data in the field of autologous stem cell transplantation (ASCT) in both groups of patients will be reviewed.

Original languageSpanish
Pages (from-to)16-26
Number of pages11
JournalRevisiones en Cancer
Issue number1
StatePublished - Jan 1 2003



  • Aggressive lymphomas
  • Autologous
  • Bone marrow transplant
  • High dose therapy
  • Indolent lymphomas
  • Outcome

ASJC Scopus subject areas

  • Oncology

Cite this